Parallel Advisors LLC Has $376,000 Stock Holdings in Takeda Pharmaceutical Co. $TAK

Parallel Advisors LLC grew its position in Takeda Pharmaceutical Co. (NYSE:TAK) by 22.6% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 24,338 shares of the company’s stock after purchasing an additional 4,485 shares during the period. Parallel Advisors LLC’s holdings in Takeda Pharmaceutical were worth $376,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FNY Investment Advisers LLC acquired a new stake in shares of Takeda Pharmaceutical in the 1st quarter valued at $37,000. Farther Finance Advisors LLC lifted its position in Takeda Pharmaceutical by 29.2% during the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company’s stock worth $69,000 after buying an additional 1,045 shares in the last quarter. Fifth Third Bancorp lifted its position in Takeda Pharmaceutical by 85.5% during the 1st quarter. Fifth Third Bancorp now owns 5,232 shares of the company’s stock worth $78,000 after buying an additional 2,411 shares in the last quarter. GAMMA Investing LLC lifted its position in Takeda Pharmaceutical by 22.6% during the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock worth $105,000 after buying an additional 1,296 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Takeda Pharmaceutical during the 1st quarter worth about $125,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Takeda Pharmaceutical stock opened at $15.07 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.59 and a debt-to-equity ratio of 0.60. Takeda Pharmaceutical Co. has a 1 year low of $12.80 and a 1 year high of $15.69. The company has a market cap of $47.95 billion, a PE ratio of 50.23 and a beta of 0.22. The company’s 50-day moving average is $14.82 and its two-hundred day moving average is $14.84.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The company had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Equities analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Zacks Research downgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.